OBJECTIVES: The major clinical side effect of the ERBB2-targeted breast cancer therapy, trastuzumab, is a decline in the left ventricular ejection fraction (LVEF). Improved markers are needed to better identify patients susceptible to cardiotoxicity. METHODS: The NCCTG N9831 trial compared adjuvant doxorubicin and cyclophosphamide followed by either weekly paclitaxel (arm A); paclitaxel then trastuzumab (arm B); or concurrent paclitaxel and trastuzumab (arm C) in patients with HER2-positive breast cancer. A genome-wide association study was performed on all patients with available DNA (N=1446). We used linear regression to identify single nucleotide polymorphisms (SNPs) associated with decline in LVEF, adjusting for age, baseline LVEF, antihypertensive medications, and the first two principle components. RESULTS: In total, 618 863 SNPs passed quality control and DNA from 1191 patients passed genotyping quality control and were identified as Whites of non-Hispanic origin. SNPs at six loci were associated with a decline in LVEF (P=7.73×10 to 8.93×10), LDB2, BRINP1, chr6 intergenic, RAB22A, TRPC6, and LINC01060, in patients who received chemotherapy plus trastuzumab (arms BC, N=800). None of these loci were significant in patients who received chemotherapy only (arm A, N=391) and did not increase in significance in the combined analysis of all patients. We did not observe association, P<0.05, with SNPs previously associated with trastuzumab-induced cardiotoxicity at ERBB2, I655V, and P1170A. We replicated association, P<0.05, with SNPs previously associated with anthracycline-induced cardiotoxicity at CBR3 and ABCB1. CONCLUSION: Our study identified six putative novel cardiotoxicity loci in patients treated with combination chemotherapy and trastuzumab that require further investigation and confirmed known associations of anthracycline-induced cardiotoxicity.
RCT Entities:
OBJECTIVES: The major clinical side effect of the ERBB2-targeted breast cancer therapy, trastuzumab, is a decline in the left ventricular ejection fraction (LVEF). Improved markers are needed to better identify patients susceptible to cardiotoxicity. METHODS: The NCCTG N9831 trial compared adjuvant doxorubicin and cyclophosphamide followed by either weekly paclitaxel (arm A); paclitaxel then trastuzumab (arm B); or concurrent paclitaxel and trastuzumab (arm C) in patients with HER2-positive breast cancer. A genome-wide association study was performed on all patients with available DNA (N=1446). We used linear regression to identify single nucleotide polymorphisms (SNPs) associated with decline in LVEF, adjusting for age, baseline LVEF, antihypertensive medications, and the first two principle components. RESULTS: In total, 618 863 SNPs passed quality control and DNA from 1191 patients passed genotyping quality control and were identified as Whites of non-Hispanic origin. SNPs at six loci were associated with a decline in LVEF (P=7.73×10 to 8.93×10), LDB2, BRINP1, chr6 intergenic, RAB22A, TRPC6, and LINC01060, in patients who received chemotherapy plus trastuzumab (arms BC, N=800). None of these loci were significant in patients who received chemotherapy only (arm A, N=391) and did not increase in significance in the combined analysis of all patients. We did not observe association, P<0.05, with SNPs previously associated with trastuzumab-induced cardiotoxicity at ERBB2, I655V, and P1170A. We replicated association, P<0.05, with SNPs previously associated with anthracycline-induced cardiotoxicity at CBR3 and ABCB1. CONCLUSION: Our study identified six putative novel cardiotoxicity loci in patients treated with combination chemotherapy and trastuzumab that require further investigation and confirmed known associations of anthracycline-induced cardiotoxicity.
Authors: Marion Procter; Thomas M Suter; Evandro de Azambuja; Urania Dafni; Veerle van Dooren; Susanne Muehlbauer; Miguel Angel Climent; Ernst Rechberger; Walter Tsang-Wu Liu; Mazakasu Toi; R Charles Coombes; David Dodwell; Olivia Pagani; Jorge Madrid; Marcia Hall; Shin-Cheh Chen; Christian Focan; Michael Muschol; Dirk J van Veldhuisen; Martine J Piccart-Gebhart Journal: J Clin Oncol Date: 2010-06-07 Impact factor: 44.544
Authors: Evadnie Rampersaud; Daniel D Kinnamon; Kara Hamilton; Sawsan Khuri; Ray E Hershberger; Eden R Martin Journal: Ann Hum Genet Date: 2010-02-18 Impact factor: 1.670
Authors: Javier G Blanco; Can-Lan Sun; Wendy Landier; Lu Chen; Diego Esparza-Duran; Wendy Leisenring; Allison Mays; Debra L Friedman; Jill P Ginsberg; Melissa M Hudson; Joseph P Neglia; Kevin C Oeffinger; A Kim Ritchey; Doojduen Villaluna; Mary V Relling; Smita Bhatia Journal: J Clin Oncol Date: 2011-11-28 Impact factor: 44.544
Authors: Henk Visscher; Colin J D Ross; S Rod Rassekh; Amina Barhdadi; Marie-Pierre Dubé; Hesham Al-Saloos; George S Sandor; Huib N Caron; Elvira C van Dalen; Leontien C Kremer; Helena J van der Pal; Andrew M K Brown; Paul C Rogers; Michael S Phillips; Michael J Rieder; Bruce C Carleton; Michael R Hayden Journal: J Clin Oncol Date: 2011-09-06 Impact factor: 44.544
Authors: Folefac Aminkeng; Colin J D Ross; Shahrad R Rassekh; Soomi Hwang; Michael J Rieder; Amit P Bhavsar; Anne Smith; Shubhayan Sanatani; Karen A Gelmon; Daniel Bernstein; Michael R Hayden; Ursula Amstutz; Bruce C Carleton Journal: Br J Clin Pharmacol Date: 2016-06-30 Impact factor: 4.335
Authors: Daniel L Hertz; Megan V Caram; Kelley M Kidwell; Jacklyn N Thibert; Christina Gersch; Nicholas J Seewald; Jeffrey Smerage; Melvyn Rubenfire; N Lynn Henry; Kathleen A Cooney; Monika Leja; Jennifer J Griggs; James M Rae Journal: Pharmacogenomics Date: 2016-01-22 Impact factor: 2.533
Authors: Maria Kauppi; Anne Simonsen; Bjørn Bremnes; Amandio Vieira; Judy Callaghan; Harald Stenmark; Vesa M Olkkonen Journal: J Cell Sci Date: 2002-03-01 Impact factor: 5.285
Authors: Marelize Swart; Wesley M Stansberry; Victoria M Pratt; Elizabeth B Medeiros; Patrick J Kiel; Fei Shen; Bryan P Schneider; Todd C Skaar Journal: J Mol Diagn Date: 2019-02-20 Impact factor: 5.568
Authors: Mohammed Al-Sadawi; Yasin Hussain; Robert S Copeland-Halperin; Jonathan N Tobin; Chaya S Moskowitz; Chau T Dang; Jennifer E Liu; Richard M Steingart; Michelle N Johnson; Anthony F Yu Journal: Am J Cardiol Date: 2021-02-20 Impact factor: 2.778